Form 4: Bio-Rad Director Allison Schwartz Reports Stock Transactions

Bio-Rad Laboratories Director Allison Schwartz reported the acquisition of 147 Class A common shares through RSU vesting and the disposition of 55 shares for tax purposes.

Summary

• Allison Schwartz, a Director at Bio-Rad Laboratories, Inc., reported changes in her beneficial ownership of company stock.
• On September 1, 2025, Schwartz acquired 147 shares of Bio-Rad Class A Common Stock through the vesting of restricted stock units (RSUs).
• Concurrently, 55 shares of Bio-Rad Class A Common Stock were disposed of at a price of $297.88 per share, likely to cover tax obligations related to the RSU vesting.
• Following these transactions, Schwartz directly owns 1,397 shares of Bio-Rad Class A Common Stock.
• The transactions involved the vesting of RSUs originally granted on September 1, 2021 (31 units), September 1, 2022 (42 units), and September 1, 2023 (74 units).
• After these vestings, 150 restricted stock units from the September 1, 2023 grant remain beneficially owned.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to RSU vesting and tax withholding. The director's net increase in direct share ownership is a minor positive, indicating continued alignment with shareholder interests.

Positives

• Director Allison Schwartz increased her direct ownership of Bio-Rad Class A Common Stock by a net of 92 shares (147 acquired 55 disposed) through the vesting of restricted stock units, indicating continued equity participation.
• The vesting of restricted stock units demonstrates the company's commitment to long-term incentive plans for its directors, aligning their interests with shareholders.

Negatives

• 55 shares were disposed of at $297.88 per share, likely for tax withholding, which reduces the director's overall direct shareholding from the gross vested amount.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The director's continued equity ownership aligns her interests with those of shareholders. The disposition of shares for tax purposes is a routine event and does not indicate a lack of confidence.
• Employees: The RSU vesting process is a standard component of executive compensation, which can motivate and retain key personnel.

Next Steps

• Future vesting events for the remaining 150 restricted stock units granted on September 1, 2023, will occur in subsequent annual installments.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and subsequent share disposition for tax purposes by a director. While there's a net increase in the director's direct shareholding, the transaction volume is not significant enough to warrant a change in investment thesis based solely on this report. It reflects standard equity compensation practices and continued insider ownership, which is generally neutral to slightly positive.

Keywords

Bio-Rad Laboratories, BIO, BIO.B, Allison Schwartz, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Director Stock Ownership, Equity Compensation